SynthesisInternational journal of clinical oncology2021
Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.
Synthesis in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical practice guidelines for duodenal cancer 2025.Journal of gastroenterology · 2026Review
- Limited (pancreas-sparing) surgical resections for non-ampullary duodenal neoplasms: indications, surgical techniques and outcomes.Updates in surgery · 2026Article
- Laparoscopic and endoscopic cooperative surgery in gastrointestinal tumors: current applications, oncologic considerations, and future directions.Frontiers in oncology · 2026Review
- Pancreas-preserving segmental duodenectomy for duodenal malignancy: two case reports.Frontiers in oncology · 2026Article
- Survival benefit of adjuvant chemotherapy for duodenal adenocarcinoma: a retrospective cohort study and propensity score-matched analysis.Translational cancer research · 2025Article
- [Primary small bowel malignancies].Chirurgie (Heidelberg, Germany) · 2025Review
- Application of imaging technology for the diagnosis of malignancy in the pancreaticobiliary duodenal junction (Review).Oncology letters · 2024Review
- The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas.Medicina (Kaunas, Lithuania) · 2023Article
- Endoscopy in surgery.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Article
- Segmental resection with partial mesopancreatic and mesojejunal excision (pMME) for duodenal carcinoma of the third or fourth portion.Langenbeck's archives of surgery · 2022Article
- Surgical treatment and survival analysis of primary duodenal malignant tumor: a retrospective cohort study.Journal of gastrointestinal oncology · 2022Article
- Pancreas-preserving partial duodenectomy for non-ampullary duodenal neoplasms: three case reports.Surgical case reports · 2022Article
- Pancreas-preserving limited duodenal resection: Minimizing morbidity without compromising oncological adequacy.Annals of hepato-biliary-pancreatic surgery · 2022Article
- Comparison of robotic and open pancreaticoduodenectomy for primary nonampullary duodenal adenocarcinoma: a retrospective cohort study.Langenbeck's archives of surgery · 2022Article
- Prognostic Factors and Lymph Node Metastasis Patterns of Primary Duodenal Cancer.World journal of surgery · 2022Article
- Rare resected eight cases of duodenal adenocarcinomas.International journal of surgery case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 2 countries.
Funding
Abstract
It is well known that surgery is the mainstay treatment for duodenal adenocarcinoma. However, the optimal extent of surgery is still under debate. We aimed to systematically review and perform a meta-analysis of limited resection (LR) and pancreatoduodenectomy for patients with duodenal adenocarcinoma. A systematic electronic database search of the literature was performed using PubMed and the Cochrane Library. All studies comparing LR and pancreatoduodenectomy for patients with duodenal adenocarcinoma were selected. Long-term overall survival was considered as the primary outcome, and perioperative morbidity and mortality as the secondary outcomes. Fifteen studies with a total of 3166 patients were analyzed; 995 and 1498 patients were treated with limited resection and pancreatoduodenectomy, respectively. Eight and 7 studies scored a low and intermediate risk of publication bias, respectively. The LR group had a more favorable result than the pancreatoduodenectomy group in overall morbidity (odd ratio [OR]: 0.33, 95% confidence interval [CI] 0.17-0.65) and postoperative pancreatic fistula (OR: 0.13, 95% CI 0.04-0.43). Mortality (OR: 0.96, 95% CI 0.70-1.33) and overall survival (OR: 0.61, 95% CI 0.33-1.13) were not significantly different between the two groups, although comparison of the two groups stratified by prognostic factors, such as T categories, was not possible due to a lack of detailed data. LR showed long-term outcomes equivalent to those of pancreatoduodenectomy, while the perioperative morbidity rates were lower. LR could be an option for selected duodenal adenocarcinoma patients with appropriate location or depth of invasion, although further studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.